We are pleased to provide details of the February edition of our C-Suite round table discussion where we will be addressing the topic of:

'The Art of Dealmaking'



The event, kindly hosted by Mills & Reeve in Cambridge, will feature keynotes from two industry experts who will share insight into the complexities of dealmaking for life sciences R&D's, including the types of deal structures, co-commercialisation, partnerships, and de-risking research.

They will also consider upstream partnership agreements, as well as the importance of protecting patents, know-how and other IP, and how conducting the appropriate levels of due diligence is absolutely critical. 

Finally we will consider the potential threats, challenges and 'poison pills' that exist in the deal making process and consider how R&Ds can stay protected, and thrive, throughout this uncertain process. 

Programme:

08.30 Guest arrival, breakfast and networking

09.00 Welcome by Stuart Rose​, CEO of OBN

Keynote one: James Fry​, Partner, Head of Life Sciences, Mills & Reeve​

Keynote two: Huw Jones​, CEO of TheraCryf ​

09.30 Moderated round table discussion between all guests

10.30 Event close

Event format: OBN's round table C-Suite Discussions are designed exclusively for senior leaders (C-Suite or equivalent) from life sciences organisations, whether R&D or those involved in providing critical support services to the industry. The purpose of these events is to generate some interesting, useful, high-level and boundary pushing discussion and debate, that creates some practical thought-leadership output.

Please note that places are limited and will be offered on an approval only basis. Complimentary tickets available for OBN Members & Academics, non-OBN Member tickets available at £75.00 plus VAT.